A Phase 3 Study of Dostarlimab as Sequential Therapy After Chemoradiotherapy Compared to Placebo in Adult Participants with Locally Advanced, Unresectable Squamous Cell Carcinoma of the Head and Neck (JADE)
Descrizione riassuntiva dello studio
This study investigates the efficacy and safety of the investigational drug Dostarlimab (PD-1 inhibitor) in adult participants with locally advanced, unresectable squamous cell carcinoma of the head and neck (also referred to as head and neck cancer). After the recommended treatment with a combination of radiation therapy and chemotherapy (chemoradiotherapy) has been completed, the screening phase begins to determine if the patient is eligible for this study. If all requirements are met, study participants will be randomly assigned to 2 groups: - Group A: Experimental group, receives Dostarlimab - Group B: Control group, receives a placebo (an identically appearing substance without active ingredient, e.g., saline). In the treatment phase (approximately 1 year), study participants will receive an intravenous infusion of either Dostarlimab or placebo for up to 11 doses (also called cycles). The first 4 cycles are administered every 3 weeks, and the following 7 cycles every 6 weeks. This is followed by a follow-up phase (approximately 4 years), during which further examinations will be conducted to determine if the cancer has recurred or worsened. The aim of the study is to investigate whether Dostarlimab can delay or reduce the risk of recurrence of head and neck cancer compared to placebo.
(BASEC)
Intervento studiato
The investigational drug Dostarlimab belongs to the class of medications known as PD-1 inhibitors (PD-1 blockers; programmed cell death-1). On certain cells of the immune system (the T cells), there is a protein called PD-1 (a protein substance). Cancer cells in the body produce a protein called PD-L1 (programmed death-ligand 1). PD-L1 can interact with PD-1 and thereby inhibit immune cells. Dostarlimab, as a PD-1 inhibitor, can block this interaction and enable the immune system to attack cancer cells again.
(BASEC)
Malattie studiate
Locally advanced, unresectable squamous cell carcinoma of the head and neck (also referred to as head and neck cancer).
(BASEC)
1. The study participant is over 18 years old and has a specific type of head and neck cancer that cannot be surgically removed. The cancer is newly diagnosed and located in the mouth, throat, or larynx. The participant has completed treatment with a combination of chemotherapy and radiation therapy, aiming to cure the cancer, and there are no signs that the cancer has spread to other parts of the body (no metastases). 2. The disease falls into one of the categories described in the protocol, according to the location of the cancer (throat and larynx) and the status of a protein called p16. The participant has provided a tissue sample from a biopsy showing that the tumor has a specific marker called PD-L1 with a value of 1 or higher. 3. The participant has completed the required amount of chemotherapy and radiation therapy according to the study guidelines. (BASEC)
Criteri di esclusione
1. Has a type of cancer in the head or neck area, but not in the throat, larynx, lower throat, or mouth. This includes cancers in areas such as the upper part of the throat, the sinuses, other areas near the nose, or other unknown areas in the head and neck region. 2. Has received prior treatments for head and neck cancer that are not part of a combined treatment of chemotherapy and radiation therapy (chemoradiotherapy). These treatments may include sole radiation, drug treatments, or surgeries. 3. Currently has side effects from previous combined chemotherapy and radiation therapy (chemoradiotherapy) that are greater than moderate (more than grade 2 on a standard scale). Participants with stable or persistent side effects (e.g., hearing loss, nerve damage) may still participate after consultation with the central study team. (BASEC)
Luogo dello studio
Basilea, Friburgo, Ginevra, Losanna, Zurigo
(BASEC)
Sponsor
GlaxoSmithKline AG
(BASEC)
Contatto per ulteriori informazioni sullo studio
Persona di contatto in Svizzera
Dr. Tomas Brezina
+41 43 253 28 87
Tomas.Brezina@clutterusz.chUniversitätsspital Zürich Klinik für Med. Onkologie und Hämatologie
(BASEC)
Informazioni scientifiche
non disponibile
Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)
Commissione etica Zurigo
(BASEC)
Data di approvazione del comitato etico
19.08.2025
(BASEC)
ID di studio ICTRP
non disponibile
Titolo ufficiale (approvato dal comitato etico)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) (BASEC)
Titolo accademico
non disponibile
Titolo pubblico
non disponibile
Malattie studiate
non disponibile
Intervento studiato
non disponibile
Tipo di studio
non disponibile
Disegno dello studio
non disponibile
Criteri di inclusione/esclusione
non disponibile
non disponibile
Endpoint primari e secondari
non disponibile
non disponibile
Data di registrazione
non disponibile
Inclusione del primo partecipante
non disponibile
Sponsor secondari
non disponibile
Contatti aggiuntivi
non disponibile
ID secondari
non disponibile
Risultati-Dati individuali dei partecipanti
non disponibile
Ulteriori informazioni sullo studio
non disponibile
Risultati dello studio
Riepilogo dei risultati
non disponibile
Link ai risultati nel registro primario
non disponibile